Investigational vaccine for Escherichia coli O157: Phase 1 study of O157 O-specific polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults

Journal of Infectious Diseases

Volumn 177, Issue 2, 1998, Pages 383-387

  Konadu, Edward Y ^b   Parke Jr , James C ^b   Tran, Hung T ^b   Bryla, Dolores A ^b   Robbins, John B ^b   Szu, Shousun C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; ESCHERICHIA COLI O157 O SPECIFIC POLYSACCHARIDE PSEUDOMONAS AERUGINOSA RECOMBINANT EXOPROTEIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; UNCLASSIFIED DRUG; VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONJUGATE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENTERITIS; ERYTHEMA; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN EXPERIMENT; IMMUNOGLOBULIN BLOOD LEVEL; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031882805     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514203     Document Type: Article

References (20)

1. Riley LW, Remis RS, Helgerson SD, et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med 1983;308:681-5.
2. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by Verotoxin-producing Escherichia coli. 3 Infect Dis 1985; 151: 775-82.
3. Griffin PM, Tauxe RV. The epidemiology of infections caused by E. coli O157:H7, other enterohemorrhagic E. coli. and the associated hemolytic uremic syndrome. Epidemiol Rev 1991; 13:60-98.
4. Bitzan M, Ludwig K, Klemt M, König H, Büren J, Müller-Wiefel DE. The role of Escherichia coli O157 infections in the classical (enteropath-ogenic) haemolytic uraemic syndrome: results of a central European, multicentre study. Epidemiol Infect 1993; 110:183-96.
5. Watanabe H, Wada A, Inagak Y, Tamura K. Outbreaks of enterohaemorrhagic Escherichia coli O157:H7 infection by two different genotype strains in Japan. Lancet 1996; 348:831-2.
6. O'Brien AD, LaVeck GD, Thompson MR, Formal SB. Production of a Shigella dysenteriae type 1 -like cytotoxin by Escherichia coli. J Infect Dis 1982:146:763-9.
7. Raghupathy P, Date A, Shastry JCM, Sudarsanam A, Jadhav M. Haemolytic-uraemic syndrome complicating Shigella dysentery in south Indian children. Br Med J 1978; 1:1518-21.
8. Bell BP, Griffin PM, Lozano P, et al. Predictors of hemolytic uremic syndrome during large outbreaks of Escherichia coli O157:H7 infections. Pediatrics 1997; 100 (in press).
9. Butler T, Islam MR, Azad MAK, Jones PK. Risk factors for development of hemolytic uremic syndrome during shigellosis. J Pediatr 1987; 110: 894-7.
10. Ørskov F, Ørskov I, Villar JA. Cattle as reservoir of Verotoxin-producing Escherichia coli O157:H7 [letter]. Lancet 1987;2:276.
11. Robbins JB, Chu C, Schneerson R. Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin Infect Dis 1982; 15:346-61.
12. Ørskov I, Ørskov F, Jann B, Jann K. Serology, chemistry, and genetics of O and K antigens of Escherichia coli. Bacteriol Rev 1977;41:667-710.
13. Levine MM, JB Kaper, RE Black, Clements ML. New knowledge on pathogenesis of bacterial enteric infections as applied to bacterial vaccine development. Microbiol Rev 1983;47:510-50.
14. Ferreccio C, Prado V, Ojeda A, et al. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am J Epidemiol 1991; 134:614-27.
15. Cohen D, Green MS, Block C, Rouach T, Ofek I. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J Infect Dis 1988; 157:1068-71.
16. Cohen D, Ashkenazi S, Green MS, et al. Double-blind vaccine-controlled randomized efficacy trial of an investigational Shigella sound conjugate vaccine in young adults. Lancet 1997;349:155-9.
17. Chart H, SM Scotland SM, Rowe B. Serum antibodies to Escherichia coli serotype O157:H7 in patients with the hemolytic uremic syndrome. J Clin Microbiol 1989;27:285-90.
18. Barrett TJ, Green JH, Griffin PM, Pavia AT, Ostroff SM, Wachsmuth IK. Enzyme-linked immunosorbent assays for detecting antibodies to Shigalike toxin I, Shiga-like toxin II and Escherichia coli O157:H7 lipopolysaccharide in human serum. Curr Microbiol 1991;23:189-95.
19. Reymond D, Johnson RP, Karmali MA, et al. Neutralizing antibodies to Escherichia coli Vero cytotoxin 1 and antibodies to O157 lipopolysaccharide in healthy farm family members and urban residents. J Clin Microbiol 1996;34:2053-7.
20. Levine MM, McEwen J, Losonsky GL, et al. Antibodies to the Shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae type I dysentery. J Clin Microbiol 1992;30:1636-41.